NCT02777931View on ClinicalTrials.gov

Efficacy and Safety of NFC-1 in Adolescents With Genetic Disorders Impacting mGluR and ADHD

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

February 10, 2017

Study Completion Date

February 17, 2017

Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
DRUG

NFC-1

NFC-1 is supplied as size 2 hard gelatin capsules.

DRUG

Placebo

Matching placebo capsules

Trial Locations (1)

21205

The Clinical Trials Center at Kennedy Krieger Institute, Baltimore

All Listed Sponsors
lead

Aevi Genomic Medicine, LLC, a Cerecor company

INDUSTRY

NCT02777931 - Efficacy and Safety of NFC-1 in Adolescents With Genetic Disorders Impacting mGluR and ADHD | Biotech Hunter | Biotech Hunter